Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0N85H)

Drug Name
Vidarabine Drug Info
Synonyms
Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine
Therapeutic ClassAntiviral Agents
Cross-matching ID
PubChem CID
21704
ChEBI ID
CHEMBL45327
CAS Number
CAS 5536-17-4
TTD Drug ID
D0NI0C

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.12 0.00e+0 34/36 (94.44%) PCNA;RPA3;POLE2;...
Cell cycle 2.07 4.41e-3 110/124 (88.71%) PCNA;CCND2;CCNE2;...
Mineral absorption 2.00 5.88e-3 48/60 (80%) MT1X;MT2A;MT1F;...
Systemic lupus erythematosus 1.99 4.41e-3 45/135 (33.33%) C3;C7;ACTN1;...
Complement and coagulation cascades 1.96 3.53e-3 76/85 (89.41%) CLU;CD59;C3;...
Fanconi anemia pathway 1.94 2.94e-3 36/54 (66.67%) RPA3;USP1;FANCI;...
Staphylococcus aureus infection 1.90 5.04e-3 72/95 (75.79%) C3;KRT19;CFI;...
Viral protein interaction with cytokine and cytokine re... 1.87 5.51e-3 84/100 (84%) CXCL12;CXCL13;CCL19;...
Rheumatoid arthritis 1.85 8.81e-3 78/93 (83.87%) CXCL12;TLR4;MMP1;...
Pentose and glucuronate interconversions 1.80 1.06e-2 17/34 (50%) CRYL1;AKR1B1;UGT2B28;...
Oxidative phosphorylation 1.79 1.28e-2 93/133 (69.92%) NDUFB2;NDUFAB1;ATP6V1D;...
Cytosolic DNA-sensing pathway 1.78 1.18e-2 52/63 (82.54%) CXCL10;POLR2L;IKBKE;...
Primary immunodeficiency 1.78 1.08e-2 33/38 (86.84%) ICOS;CD19;RFX5;...
Mismatch repair 1.77 1.07e-2 22/23 (95.65%) PCNA;RPA3;RFC3;...
TGF-beta signaling pathway 1.76 1.06e-2 81/94 (86.17%) THBS1;ID3;ID4;...
Homologous recombination 1.73 1.54e-2 35/41 (85.37%) RPA3;ATM;RAD54B;...
Nucleotide excision repair 1.67 3.01e-2 40/47 (85.11%) PCNA;RPA3;POLE2;...
NF-kappa B signaling pathway 1.65 3.82e-2 90/104 (86.54%) CXCL12;TLR4;CCL19;...
Glutathione metabolism 1.64 3.90e-2 43/57 (75.44%) GPX3;RRM2;LAP3;...
Cytokine-cytokine receptor interaction 1.64 3.70e-2 246/295 (83.39%) CXCL12;CXCL13;CCL19;...
Malaria 1.61 4.83e-2 44/50 (88%) TLR4;THBS1;THBS2;...
Coronavirus disease 1.60 4.83e-2 215/232 (92.67%) TLR4;CXCL10;C3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12.5uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H